Farris is pleased to have represented MTL Cannabis Corp. (CSE: MTLC), a flower-first company and leading distributor of medical cannabis and clinic services, on its strategic sale to Canopy Growth Corporation (Nasdaq: CGC; TSX: WEED), with a transaction value of approximately $179 million on a total enterprise value basis. The sale was completed under a CBCA plan of arrangement where Canopy Growth acquired all of MTL Cannabis’ outstanding equity for a mix of cash and Canopy Growth shares and settled all outstanding debt and debt-like instruments owed by MTL Cannabis.

The combined company establishes Canada’s leading medical cannabis platform and strengthens Canopy Growth’s broader business through expanded premium flower supply, enhanced operating execution and ability to meet demand in regulated international medical markets, including Europe.

MTL Cannabis was represented by a Farris transaction team led by Daniel Everall and included Tim Louman-Gardiner (Litigation), David Selley (Competition), Kurtis Harms (Competition), Ben Kaardal (M&A, Securities), and Nick Allen (Banking).

For a copy of the press release, click here.